Guardant Health, Inc. (NASDAQ: GH) and Quest Diagnostics (NYSE: DGX) announced on September 24, 2025 a broad strategic collaboration to make Guardant’s Shield™ blood‑based colorectal cancer screening test available to physicians and patients served by Quest in the United States.
The Shield test is the first FDA‑approved blood test for primary colorectal cancer screening, and the partnership will leverage Quest Diagnostics’ extensive laboratory network to broaden access to the test across the country.
By extending Shield’s reach through Quest’s distribution and clinical services, Guardant Health positions itself to capture a larger share of the colorectal cancer screening market and accelerate revenue growth from its flagship product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.